BSEAGM/EGM2d ago · 18 Aug 2026, 05:07 pm
Notice of 37th AGM and Annual Report
Pharmaids Pharmaceuticals Ltd · 524572
✦ AI SummaryResults
Pharmaids Pharmaceuticals Ltd has announced the notice of its 37th Annual General Meeting (AGM) and Annual Report for the financial year 2025-2026. The AGM will be held on September 11, 2026, and the Annual Report is available on the company's website and through email to registered members.
Analysis Scores
Earnings Impact0/10
Growth Catalyst0/10
Governance Concern0/10
Regulatory Risk0/10
Balance Sheet Risk0/10
Liquidity Impact0/10
Market Sentiment0/10
✦ Ask a Question
Ask anything about this announcement — AI will answer based on the filing content.
Full Announcement
Pharmaids Pharmaceuticals Ltd - 524572 - Notice Of 37Th Annual General Meeting And Annual Report
Attachments (1)
📄pdf
Download →
03402968-35d4-4b8b-91b7-f25dacbc8747.pdf
View document text
Date: 18.08.2026
BSE Limited
Phiroze Jeejeebhoy Towers, Dalal Street
Mumbai – 400001
Dear Sir/Madam,
Scrip Code: 524572 | Scrip ID: PHARMAID | ISIN: INE117D01018
Sub: Notice of Convening the 37th Annual General Meeting (“AGM”) and the Annual
Report for the Financial Year 2025-2026.
Pursuant to Regulation 34(1) of the Securities and Exchange Board of India (Listing
Obligations and Disclosure Requirements) Regulations, 2015 (“Listing Regulations”), we
enclose herewith the following for your information and records:
1. Notice of 37th Annual General Meeting scheduled to be held on Friday, September 11,
2026, at 12:00 noon (IST).
2. Copy of Annual Report for Financial Year 2025-2026.
The Annual Report of the Company for the Financial Year 2025-26 along with Notice
convening the AGM has been sent only through E-mail to all those Members whose E-mail
addresses are registered with the Company or with their respective Depository Participant(s)
(DP). Further, in accordance with Regulation 36(1)(b) of the Listing Regulations, a letter
containing the web-link and path for accessing the Annual Report for FY 2025-26 is being sent
to all those Members who have not registered their email ids with the Company/RTA/DPs.
The aforesaid documents will also be available on the website of the Company at
www.pharmaids.com
In terms of Section 108 of the Companies Act, 2013 read with Rule 20 of the Companies
(Management and Administration) Rules, 2014 as substituted by the Companies (Management
and Administration) Amendment Rules, 2015 (‘the Rules’) and Regulation 44 of the Securities
Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations,
2015, the Company is providing the Remote E-Voting Facility to the Members to cast their
vote by electronic means on all the Business items forming part of the Notice of the AGM. The
Company has engaged services of Central Depository Service (India) Limited (CDSL) for
providing E-Voting facility.
PHARMAIDS PHARMACEUTICALS LIMITED (CIN: L52520KA1989PLC173979)
Registered Office.: Unit #201, Brigade Rubix, 20/14, HMT Factory Road, Peenya Plantation, Bangalore 560013 INDIA
Phone: 080-49784319 Email: compliance@pharmaids.com WEB: www.pharmaids.com
The details pursuant to the provisions of the Companies Act 2013 and the Rules are given here
under:
Events Day and Date
Cut-off date Friday 04, September 2026
E-voting Commencement date Tuesday 08, September 2026
E-voting end date Thursday 10, September 2026
Remote e-voting will be disabled by the RTA upon the expiry of the aforesaid period.
Members are requested to refer to the detailed procedure for Remote E-Voting / E-Voting at
AGM as provided in the Notice of 37th Annual General Meeting.
This is for your kind information and record.
Thanking you
For Pharmaids Pharmaceuticals Limited
Prasanna Subramanya Bhat
(Company Secretary & Compliance Officer)
PHARMAIDS PHARMACEUTICALS LIMITED (CIN: L52520KA1989PLC173979)
Registered Office.: Unit #201, Brigade Rubix, 20/14, HMT Factory Road, Peenya Plantation, Bangalore 560013 INDIA
Phone: 080-49784319 Email: compliance@pharmaids.com WEB: www.pharmaids.com
ANNUAL
REPORT
2025 ‑ 26
PHARMAIDS
PHARMACEUTICALS
LIMITED
37th Annual Report
PHARMAIDS PHARMACEUTICALS LIMITED
CIN:L52520KA1989PLC173979
CORPORATE INFORMATION
BOARD OF DIRECTORS
Mr. Pattamadai Natarajasarma Vijay Chairman (Independent Director)
Dr. Shankarappa Nagaraja Vinaya Babu Vice Chairman (Non-Executive and Non-Independent Director)
Mr. Shreedhara Shetty Non-Executive and Non-Independent Director
Dr. Yogananda Moolemath Independent Director
Mr. Methuku Nagesh Independent Director
Mr. Venu Madhava Kaparthy Executive Director
Ms. Mini Manikantan Executive Director
CHIEF FINANCIAL OFFICER
Mr. Balagangadhara B C
COMPANY SECRETARY & COMPLIANCE OFFICER SECRETARIAL AUDITOR
Mr. Prasanna Subramanya Bhat M/s Kashinath Sahu & Co,
Mem No.- A48828 Practising Company Secretaries
Hyderabad
STATUTORY AUDITOR INTERNAL AUDITOR
M/s PPKG & Co. T N Raghavendra
Chartered Accountants Chartered Accountant
Hyderabad Tumkur, Karnataka
REGISTRAR & SHARE TRANSFER AGENT BANKERS
M/s Venture Capital and Corporate Investments Pvt Ltd. Canara Bank
“Aurum”, Door No.4-50/P-II/57/4F &5F, Plot No. 57, 4th ICICI Bank
& 5th floors, Jayabheri Enclave Phase- II, Gachibowli Axis Bank
Hyderabad – 500032 LISTING
Phone No. 404-23818475, 23868275, 35164940 BSE Limited
Website - www.vccipl.com Security code-524572
REGISTERED OFFICE SUBSIDIARIES
Unit #201, 2nd Floor, Brigade Rubix, 20/14, HMT Factory Adita Bio Sys Private Limited
Main Road, Peenya Plantation, Bangalore - 560013 Spring Labs (firm)
Karnataka, India
Telephone No.- 080- 49784319
Email- Id - compliance@pharmaids.com
Website – www.pharmaids.com
INDEX
S.No. Contents Page No.
1. About this Report 3
2. About Pharmaids 4
3. Board’s Report 5
4. Annexures to Board’s Report 22
5. Management Discussion and Analysis Report 38
6. Corporate Governance Report 41
7. Annexures to Corporate Governance Report 61
8. Standalone Financial Statements
9. Independent Auditors’ Report 65
10. Balance sheet 76
11. Statement of P&L, Cash Flow & Changes in Equity 78
12. Notes to Standalone Financial Statements 83
13. Consolidated Financial Statements
14. Independent Auditors’ Report 121
15. Balance sheet 129
16. Statement of P&L, Cash Flow & Changes in Equity 131
17. Notes to Consolidated Financial Statements 137
18. Notice of 37th Annual General Meeting 176
About this report
We are pleased to present the Thirty-Seventh Annual Report, for the financial year 2025-26. This report
provides an overview of your Company’s operations, financial and non-financial performance during
the year. Further, in this report, we have highlighted the key opportunities and challenges faced by our
industry, as well as our policies and procedures for ensuring compliance and good governance. The
report aims to provide a detailed insight into our financial and non-financial disclosures, encompassing
our leadership, culture, and value creation strategy for stakeholders.
Responsibility statement
The Board firmly believes that this report is a fair representation of your Company’s financial, non-
financial and operational performance and addresses all material topics relevant to the company for FY
2025-26. The Board acknowledges that contents of this report have been prepared by respective
functions and under the guidance of the management.
Certain statements in this report concerning our future growth prospects are forward-looking
statements, which involve a number of risks, and uncertainties that could cause actual results to differ
materially from those in such forward-looking statements due to risks or uncertainties associated with
our expectations with respect to, but not limited to, our ability to successfully implement our strategy
and our growth and expansion plans, technological changes, our exposure to market risks, general
economic and political conditions in India which have an impact on our business activities or
investments, changes in the laws and regulations that apply to the industry in which the Company
operates. The Company does not undertake to update any forward-looking statements that may be made
from time to time by or on behalf of the Company.
About Pharmaids
Incorporated in March 1989, we are a Public Limited Company listed on BSE Ltd since 1994. The new
promoters, namely Dr. Shankarappa Nagaraja Vinaya Babu and Tumkur Trade Center Private Limited,
came on board with effect from 17th September, 2025.
With a unique business strategy, a modest investment plan and with a bold vision to be a global player
in this business, we strive to provide high quality innovation and research, development, and
manufacturing services to our partners. We have onboarded a team having thorough scientific,
management and operational experience. We have also been able to bring in Independent Board
members with excellent & longstanding experience. The Company and our subsidiaries work for clients
around
[Showing first 8,000 characters — download PDF for full document]